Harrow Health, Inc. (HROW)
Market Cap | 737.71M |
Revenue (ttm) | 138.68M |
Net Income (ttm) | -31.33M |
Shares Out | 35.38M |
EPS (ttm) | -0.92 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 254,799 |
Open | 20.93 |
Previous Close | 21.05 |
Day's Range | 20.36 - 21.00 |
52-Week Range | 7.60 - 22.63 |
Beta | 0.88 |
Analysts | Strong Buy |
Price Target | 28.00 (+34.29%) |
Earnings Date | Aug 7, 2024 |
About HROW
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic e... [Read more]
Full Company ProfileFinancial Performance
In 2023, Harrow Health's revenue was $130.19 million, an increase of 46.95% compared to the previous year's $88.60 million. Losses were -$24.41 million, 73.3% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price forecast is $28.0, which is an increase of 34.29% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/b/x/press13-2487603.jpg)
Harrow Provides TRIESENCE® Relaunch Update
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce the successful manufacture of the first of three com...
![](https://cdn.snapi.dev/images/v1/z/8/press2-2465906.jpg)
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first pati...
![](https://cdn.snapi.dev/images/v1/a/1/press9-2463269.jpg)
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to announce results from its ESSENCE‑2 open-label extension (OLE...
![](https://cdn.snapi.dev/images/v1/j/q/conf2-2431695.jpg)
Harrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two inves...
![](https://cdn.snapi.dev/images/v1/k/c/press11-2428062.jpg)
Harrow Announces First Quarter 2024 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company a...
![](https://cdn.snapi.dev/images/v1/u/z/press5-2426548.jpg)
Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, H...
![](https://cdn.snapi.dev/images/v1/j/l/press20-2390640.jpg)
Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ende...
![](https://cdn.snapi.dev/images/v1/r/q/press8-2351948.jpg)
Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing
NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. (“Melt”), a clinical‑stage pharmaceutical company developing novel approaches for procedural sedation, today announced the completion of i...
![](https://cdn.snapi.dev/images/v1/k/r/press5-2332014.jpg)
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the fourth quarter and year ended December 31, 2023. The Compan...
![](https://cdn.snapi.dev/images/v1/s/i/press12-2308128.jpg)
Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will release its financial results for the fourth q...
![](https://cdn.snapi.dev/images/v1/o/b/press14-2279262.jpg)
Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products
NASHVILLE, Tenn. & TORONTO--(BUSINESS WIRE)---- $HROW--Harrow, Inc. (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, and Apotex Inc. (“Apotex”), Canada's largest pharmaceutical company, ...
![](https://cdn.snapi.dev/images/v1/s/4/press13-2248409.jpg)
Harrow Announces New Appointments to its Board of Directors
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to ...
![](https://cdn.snapi.dev/images/v1/k/p/press11-2225415.jpg)
Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑...
![](https://cdn.snapi.dev/images/v1/z/j/press6-2214398.jpg)
Harrow Partners with Leading Healthcare Market Access Technology Platforms
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has partnered with three leading healthcare technology platfo...
![](https://cdn.snapi.dev/images/v1/t/p/press10-2175522.jpg)
Harrow Completes Transfer of the TRIESENCE® New Drug Application
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application ...
![](https://cdn.snapi.dev/images/v1/z/s/conf4-2164951.jpg)
Harrow to Present at Two Investor Conferences in November
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that Mark L. Baum, Chief Executive Officer, and Andrew Boll, Chief Fi...
![](https://cdn.snapi.dev/images/v1/f/s/press1-2155494.jpg)
Harrow Announces Third Quarter 2023 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2023. The...
![](https://cdn.snapi.dev/images/v1/n/l/conf15-2127758.jpg)
Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the third quarter ende...
![](https://cdn.snapi.dev/images/v1/o/b/press15-2116912.jpg)
Harrow Completes Transfer of NDAs and Launches FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, and ZERVIATE® in the U.S.
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Applications...
![](https://cdn.snapi.dev/images/v1/q/4/press15-2083507.jpg)
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc.
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health...
![](https://cdn.snapi.dev/images/v1/n/t/press17-2015642.jpg)
Harrow Announces Second Quarter 2023 Financial Results
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced results for the second quarter and six months ended June 30, 2023. Th...
![](https://cdn.snapi.dev/images/v1/a/j/press19-1996381.jpg)
Harrow Launches VIGAMOX® in the U.S.
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (NASDAQ: HROW), a leading U.S. eyecare pharmaceutical company, today announced the completion of the transfer to Harrow of the New Drug Application ...
![](https://cdn.snapi.dev/images/v1/i/w/conf18-1989014.jpg)
Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the second quarter end...
![](https://cdn.snapi.dev/images/v1/o/t/press20-1977550.jpg)
Harrow Prices $60 Million Public Offering of Common Stock
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,28...
![](https://cdn.snapi.dev/images/v1/f/t/press7-1976981.jpg)
Harrow Acquires Santen's Branded Ophthalmic Portfolio
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliates of Santen Pharmaceutical Co...